Takeda Pharmaceutical TKPHF Stock
Takeda Pharmaceutical Price Chart
Takeda Pharmaceutical TKPHF Financial and Trading Overview
| Takeda Pharmaceutical stock price | 42 USD |
| Previous Close | 37.97 USD |
| Open | 42 USD |
| Bid | 39.92 USD x 80000 |
| Ask | 44.09 USD x 80000 |
| Day's Range | 42 - 42 USD |
| 52 Week Range | 26.44 - 42 USD |
| Volume | 125 USD |
| Avg. Volume | 4.49K USD |
| Market Cap | 67.09B USD |
| Beta (5Y Monthly) | 0.1 |
| PE Ratio (TTM) | 300 |
| EPS (TTM) | 0.14 USD |
| Forward Dividend & Yield | 1.29 (3.08%) |
| Ex-Dividend Date | March 31, 2027 |
| 1y Target Est | N/A |
TKPHF Valuation Measures
| Enterprise Value | 5.01T USD |
| Trailing P/E | 300 |
| Forward P/E | 51.851852 |
| PEG Ratio (5 yr expected) | 0.47 |
| Price/Sales (ttm) | 0.01429565 |
| Price/Book (mrq) | 1.4277594 |
| Enterprise Value/Revenue | 1.067 |
| Enterprise Value/EBITDA | 3.719 |
Trading Information
Takeda Pharmaceutical Stock Price History
| Beta (5Y Monthly) | 0.1 |
| 52-Week Change | 58.85% |
| S&P500 52-Week Change | 10.62% |
| 52 Week High | 42 USD |
| 52 Week Low | 26.44 USD |
| 50-Day Moving Average | 36.89 USD |
| 200-Day Moving Average | 34.43 USD |
TKPHF Share Statistics
| Avg. Volume (3 month) | 4.49K USD |
| Avg. Daily Volume (10-Days) | 10.42K USD |
| Shares Outstanding | 1.6B |
| Float | 1.59B |
| Short Ratio | N/A |
| % Held by Insiders | 0.10% |
| % Held by Institutions | 50.18% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 202 |
| Trailing Annual Dividend Yield | 531.99% |
| 5 Year Average Dividend Yield | 443.00% |
| Payout Ratio | 9.0502 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | March 31, 2026 |
| Most Recent Quarter (mrq) | September 30, 2026 |
| Next Fiscal Year End | March 31, 2027 |
Profitability
| Profit Margin | 0.86% |
| Operating Margin (ttm) | 24.37% |
| Gross Margin | 64.77% |
| EBITDA Margin | 28.68% |
Management Effectiveness
| Return on Assets (ttm) | 3.18% |
| Return on Equity (ttm) | 0.56% |
Income Statement
| Revenue (ttm) | 4.69T USD |
| Revenue Per Share (ttm) | 2964.66 USD |
| Quarterly Revenue Growth (yoy) | 6.70% |
| Gross Profit (ttm) | 3.04T USD |
| EBITDA | 1.35T USD |
| Net Income Avi to Common (ttm) | 40.8B USD |
| Diluted EPS (ttm) | 0.14 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 418.53B USD |
| Total Cash Per Share (mrq) | 262.56 USD |
| Total Debt (mrq) | 5.36T USD |
| Total Debt/Equity (mrq) | 72.23 USD |
| Current Ratio (mrq) | 1.151 |
| Book Value Per Share (mrq) | 29.416721 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 879.67B USD |
| Levered Free Cash Flow (ttm) | 707.47B USD |
Profile of Takeda Pharmaceutical
| Country | United States |
| State | N/A |
| City | Chuo |
| Address | 1-1, Nihonbashi-Honcho 2-chome |
| ZIP | 103-8668 |
| Phone | 81 3 3278 2111 |
| Website | https://www.takeda.com |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector(s) | Healthcare |
| Full Time Employees | 47029 |
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Replagal, Vpriv, Adynovate/Adynovi, Livtencity, ADZYNMA, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Flexbumin, Adcetris, Leuplin/Enantone, Ninlaro, Iclusig, FRUZAQLA, Alunbrig, vyvanse/elvanse, Trintellix, and QDENGA brands. It has licensing and collaboration for the development and commercialization of products with Arrowhead Pharmaceuticals, Cour Pharmaceuticals, Engitix, Halozyme, Mirum Pharmaceuticals, Ucsd/Fortis Advisors, Zedira/Dr. Falk Pharma, Ac Immune, Acurastem, Anima Biotech, Biomarin, Denali Therapeutics, Luxna Biotech, Neurocrine Biosciences, Peptidream, Abbvie, Adimab, Ascentage Pharma, Crescendo Biologics, Exelixis, F-Star, Gsk, Heidelberg Pharma, Innovent Biologics, Keros Therapeutics, Kumquat Biosciences, Protagonist Therapeutics, Halozyme, Kamada, Johnson & Johnson/Momenta Pharmaceuticals, Previpharma, Novavax, Bridgene Biosciences, Charles River Laboratories, Iambic Therapeutics, Ipsen, Km Biologics, Massachusetts Institute Of Technology, and Nabla Bio. The company operates in Japan, the United States. Europe, Canada, Latin America, China, Asia, Russia/Commonwealth of Independent States, the Middle East, Oceania, and Africa. The company was founded in 1781 and is headquartered in Chuo, Japan.
Q&A For Takeda Pharmaceutical Stock
What is a current TKPHF stock price?
Takeda Pharmaceutical TKPHF stock price today per share is 42 USD.
How to purchase Takeda Pharmaceutical stock?
You can buy TKPHF shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Takeda Pharmaceutical?
The stock symbol or ticker of Takeda Pharmaceutical is TKPHF.
Which industry does the Takeda Pharmaceutical company belong to?
The Takeda Pharmaceutical industry is Drug Manufacturers - Specialty & Generic.
How many shares does Takeda Pharmaceutical have in circulation?
The max supply of Takeda Pharmaceutical shares is 1.6B.
What is Takeda Pharmaceutical Price to Earnings Ratio (PE Ratio)?
Takeda Pharmaceutical PE Ratio is 300.00000000 now.
What was Takeda Pharmaceutical earnings per share over the trailing 12 months (TTM)?
Takeda Pharmaceutical EPS is 0.14 USD over the trailing 12 months.
Which sector does the Takeda Pharmaceutical company belong to?
The Takeda Pharmaceutical sector is Healthcare.
